Acoramidis Snags FDA Approval for ATTR Cardiomyopathy

(MedPage Today) -- Acoramidis (Attruby) gained FDA approval for treating wild-type or variant transthyretin (TTR) amyloidosis cardiomyopathy (ATTR-CM), BridgeBio Pharma announced.
Offering patients near-complete TTR stabilization in an oral tablet...